Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 1;20(3):440-450.
doi: 10.2215/CJN.0000000611. Epub 2025 Jan 29.

Favorable Living Donor Kidney Transplantation Outcomes within a National Kidney Exchange Program: A Propensity Score-Matching Analysis

Stijn C van de Laar  1   2 , Annelies E de Weerd  3 , Frederike J Bemelman  4 , Mirza M Idu  5 , Aiko P J de Vries  6   7 , Ian P J Alwayn  7   8 , Stefan P Berger  9 , Robert A Pol  10 , Arjan D van Zuilen  11 , Raechel J Toorop  12 , Luuk B Hilbrands  13 , Paul P C Poyck  14 , Maarten H L Christiaans  15 , Jorinde H H van Laanen  16 , Jacqueline van de Wetering  3 , Hendrikus J A N Kimenai  1 , Marlies E J Reinders  3 , Robert J Porte  1 , Frank J M F Dor  1   2   17 , Robert C Minnee  1
Affiliations

Favorable Living Donor Kidney Transplantation Outcomes within a National Kidney Exchange Program: A Propensity Score-Matching Analysis

Stijn C van de Laar et al. Clin J Am Soc Nephrol. .

Abstract

Key Points:

  1. KEP recipients have comparable long-term graft survival to direct living donor kidney transplantation recipients, which underscores the need to prioritize KEP over other's therapies.

  2. Our outcomes can be achieved regardless of whether the donor travels or the graft is transported, offering flexibility in program implementation.

Background: KEPs (kidney exchange programs) facilitate living donor kidney transplantations (LDKTs) for patients with incompatible donors, who are typically at higher risk than non-KEP patients because of higher sensitization and longer dialysis vintage. We conducted a comparative analysis of graft outcomes and risk factors for both KEP and non-KEP living donor kidney transplants.

Methods: All LDKTs performed in The Netherlands between 2004 and 2021 were included. The primary outcome measures were 1-, 5-, and 10-year death-censored graft survival. The secondary outcome measures were delayed graft function, graft function, rejection rates, and patient survival. We used a propensity score–matching model to account for differences at baseline.

Results: Of 7536 LDKTs, 694 (9%) were transplanted through the KEP. Ten-year graft survival was similar for KEP (0.916; 95% confidence interval, 0.894 to 0.939) and non-KEP (0.919; 0.912 to 0.926, P = 0.82). We found significant differences in 5-year rejection (12% versus 7%) and 5-year patient survival (KEP: 84%, non-KEP: 90%), which was nonsignificant after propensity score matching. Significant risk factors of lower graft survival included high donor age, retransplantations, extended dialysis vintage, higher panel reactive antibodies, and nephrotic syndrome as the cause of ESKD.

Conclusions: Transplantation through KEP offers a viable alternative for patients lacking compatible donors, avoiding specific and invasive pre- and post-transplant treatments. KEP's similar survival rate to non-KEPs suggests prioritizing KEP LDKTs over deceased donor kidney transplantation, desensitization, and dialysis. However, clinicians should consider the identified risk factors when planning and managing pre- and post-transplant care to enhance patient outcomes. Thus, we advocate for the broad adoption of KEP and establishment in regions lacking such programs, alongside initiation and expansion of international collaborations.

PubMed Disclaimer

Conflict of interest statement

Disclosure forms, as provided by each author, are available with the online version of the article at http://links.lww.com/CJN/C163.

References

    1. Baid-Agrawal S, Frei UA. Living donor renal transplantation: recent developments and perspectives. Nat Clin Pract Nephrol. 2007;3(1):31–41. doi:10.1038/ncpneph0383 - DOI - PubMed
    1. Held PJ, McCormick F, Ojo A, Roberts JP. A cost-benefit analysis of government compensation of kidney donors. Am J Transplant. 2016;16(3):877–885. doi:10.1111/ajt.13490 - DOI - PMC - PubMed
    1. Lumsdaine JA Wray A Power MJ, et al. . Higher quality of life in living donor kidney transplantation: prospective cohort study. Transpl Int. 2005;18(8):975–980. doi:10.1111/j.1432-2277.2005.00175.x - DOI - PubMed
    1. Tonelli M Wiebe N Knoll G, et al. . Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011;11(10):2093–2109. doi:10.1111/j.1600-6143.2011.03686.x - DOI - PubMed
    1. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. New Engl J Med. 2000;342(9):605–612. doi:10.1056/NEJM200003023420901 - DOI - PubMed

LinkOut - more resources